PMID- 2532056
OWN - NLM
STAT- MEDLINE
DCOM- 19900130
LR  - 20190613
IS  - 0006-8993 (Print)
IS  - 0006-8993 (Linking)
VI  - 505
IP  - 2
DP  - 1989 Dec 29
TI  - Reduction of motor behavioural deficits in senescence via chronic prolactin or 
      estrogen administration: time course and putative mechanisms of action.
PG  - 195-202
AB  - The effects of chronic estrogen (E2), rat prolactin (rPRL), modified ovine 
      prolactin (mPRL) administration on motor behavior (inclined screen performance) 
      and striatal dopamine (DA) (D2subtype) receptor concentrations were examined in 
      senescent (greater than 24 months of age) female rats, mPRL possesses no 
      lactotrophic activity. Administration of either E2 or rPRL was effective in 
      improving both inclined screen performance (increased time that the animal could 
      remain on the screen by 95 and 413 s, respectively, compared to highest 
      pre-injection performance) and striatal D2 receptor concentrations (14 and 20% 
      respectively). These were indications, however, from separate analyses that 
      improvements in inclined screen performance were seen prior to any increases in 
      striatal D2 receptor concentrations. These early performance increases seemed 
      instead to be the result of improved muscarinic receptor control over striatal DA 
      autoreceptor function. Later improvements in inclined screen performance (at 6-7 
      days after the E2 injections were begun) were more dependent on increased 
      striatal DA receptor concentrations. A second set of experiments which involved 
      the injection of E2 into senescent male as well as female rats indicated that 
      there were no sex differences in improvements in inclined screen performance, and 
      that once the E2 injections were discontinued, performance returned to 
      preadministration levels. The results are discussed in terms of two important 
      processes that may be involved in mediating enhanced inclined screen performance 
      following E2 administration: (1) enhancement of muscarinic receptor regulation of 
      DA autoreceptor function; and (2) increases in striatal DA receptor density.
FAU - Joseph, J A
AU  - Joseph JA
AD  - Molecular Physiology and Genetics Section, Nia Francis Scott Key Medical Center, 
      Baltimore, MD 21224.
FAU - Kochman, K
AU  - Kochman K
FAU - Roth, G S
AU  - Roth GS
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Brain Res
JT  - Brain research
JID - 0045503
RN  - 0 (Estrogens)
RN  - 0 (Receptors, Dopamine)
RN  - 0 (Receptors, Dopamine D2)
RN  - 4X6E73CJ0Q (Spiperone)
RN  - 5RY0UWH1JL (Oxotremorine)
RN  - 9002-62-4 (Prolactin)
RN  - VTD58H1Z2X (Dopamine)
SB  - IM
MH  - Aging/*physiology
MH  - Animals
MH  - Corpus Striatum/drug effects/*metabolism/physiology
MH  - Dopamine/metabolism/physiology
MH  - Estrogens/*pharmacology
MH  - Female
MH  - Male
MH  - Motor Activity/*drug effects/physiology
MH  - Oxotremorine/pharmacology
MH  - Prolactin/*pharmacology
MH  - Rats
MH  - Rats, Inbred Strains
MH  - Receptors, Dopamine/drug effects/*physiology
MH  - Receptors, Dopamine D2
MH  - Spiperone/metabolism
EDAT- 1989/12/29 00:00
MHDA- 1989/12/29 00:01
CRDT- 1989/12/29 00:00
PHST- 1989/12/29 00:00 [pubmed]
PHST- 1989/12/29 00:01 [medline]
PHST- 1989/12/29 00:00 [entrez]
AID - 0006-8993(89)91442-X [pii]
AID - 10.1016/0006-8993(89)91442-x [doi]
PST - ppublish
SO  - Brain Res. 1989 Dec 29;505(2):195-202. doi: 10.1016/0006-8993(89)91442-x.